Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Vertex Pharmaceuticals Incorporated
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Key Individuals == [[File:Oc lead et kewal 1000x1000.jpg|thumb|195x195px]] === Reshma Kewalramani, M.D., FASN President and CEO: === Reshma Kewalramani is a dedicated professional with over 15 years of experience in the development of new medicines, and she currently serves as the CEO and President of Vertex. Prior to her current role, she held the position of Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. Reshma earned her medical degree with honors from Boston University School of Medicine and completed the General Management Program at Harvard Business School. She is actively involved in supporting the next generation of scientists and her community, serving on several boards, including the Biomedical Science Careers Program and the Boston University School of Medicine Dean's Advisory Board. Reshma has received numerous awards and recognitions for her leadership and contributions to healthcare. Under her guidance, Vertex was ranked highly on The Commonwealth Institute's Top Women-Led Businesses in Massachusetts. [[File:Oc lead et altshuler 500x500.jpg|thumb|195x195px]] === David Altshuler, M.D., Ph.D CSO: === David is a highly passionate and enthusiastic individual with a strong background in human genetics and therapeutic innovation. He has been with Vertex since 2015, where he currently leads the internal and external innovation efforts, focusing on research, preclinical and pharmaceutical sciences, as well as corporate data strategy and technology. His goal is to discover transformative medicines for the treatment of serious diseases, and he has played a pivotal role in shaping the research pipeline at Vertex. David's academic background includes a bachelor's degree in life sciences from the Massachusetts Institute of Technology, an M.D., and a Ph.D. in genetics from Harvard Medical School. He is actively involved in various scientific and medical communities, serving on advisory boards and boards of directors for several organizations. David has received numerous awards and recognition for his contributions to the field of genetics, including being named one of the Top 20 Most Influential R&D Executives in drug development by Endpoints News in 2021. [[File:Oc lead et leiden 500x500.jpg|thumb|195x195px]] === Jeffrey Leiden, M.D., Ph.D. Executive Chairman: === Dr. Leiden is a dedicated physician and scientist who served as the Chief Executive Officer and President of the company until March 2020 and currently holds the position of Executive Chairman. Under his leadership, Vertex achieved groundbreaking advancements in treating cystic fibrosis and developed a strong pipeline for specialty markets, focusing on curative or disease-modifying therapies. He initiated collaborations for potentially curative gene-editing therapies and stem cell-based treatments. Dr. Leiden also established a program to enhance STEAM education in local communities and holds esteemed positions on boards of various institutions. His extensive academic background, philanthropic efforts, and contributions to the biopharmaceutical industry have earned him widespread recognition and respect.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)